Abstracts Archive - Page 1061 of 2607 - ACR Meeting Abstracts

Abstract Number: 1813 • 2019 ACR/ARP Annual Meeting
New Medications Are Needed for Children with Juvenile Idiopathic Arthritis
Hermine Brunner¹, Laura Schanberg ², Yukiko Kimura ³, Anne Dennos ⁴, Guy Eakin ⁵, Dominic Co ⁶, Robert Colbert ⁷, Robert Fuhlbrigge ⁸, Ellen Goldmuntz ⁹, Daniel Kingsbury ¹⁰, Sandra Mintz ¹¹, Karen Onel ¹², Cathy Patty-Resk ¹³, Lisa G. Rider ¹⁴, Rayfel Schneider ¹⁵, Allen Watts ¹⁶, Emily von-Scheven ¹⁷, Daniel J. Lovell ¹⁸, Timothy Beukelman ¹⁹ and for PRCSG Advisory Council and CARRA Registry Investigators ²⁰, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Duke University Medical Center, Durham, NC, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Arthritis Foundation, Atlanta, ⁶of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁸Department of Rheumatology, Children’s Hospital Colorado, Denver, CO, ⁹NIAID, Washingto, DC, ¹⁰LHS Pediatrics, Prtland, OR, ¹¹Children's Hospital of Los Angeles, Los Angeles, CA, ¹²Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, NY, ¹³Children's Hospital of Michigan, Detroit, MI, ¹⁴Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Cincinnati Children's Hospital MEdical Center, Cincinnati, OH, ¹⁷University of California San Francisco, San Francisco, ¹⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁹University of Alabama Birmingham, Birmingham, AL, ²⁰Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH
Background/Purpose: Existing legislation in the United States (US) promotes the study of new medications in children. Biologic disease-modifying-drugs (bDMARDs) and small molecules proven effective and…
Abstract Number: 1814 • 2019 ACR/ARP Annual Meeting
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Gabriella Giancane¹, Valentina Muratore ², Valentina Marzetti ³, Neus Quilis ³, Belen Serrano Benavente ³, Francesca Bagnasco ³, Alessandra Alongi ⁴, Adele Civino ⁵, Alessandro Consolaro ⁶ and Angelo Ravelli ⁷, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, Italy, ²IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy, ³IRCCS Gaslini, Genoa, ⁴Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genoa, ⁵Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ⁷IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: After nearly two decades from the start of the Biologic era, systematic analyses of patients with juvenile idiopathic arthritis (JIA) have shown a high…
Abstract Number: 1815 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
Nicolino Ruperto¹, Daniel J. Lovell ², John Bohnsack ³, Johannes Breedt ⁴, Michel Fischbach ⁵, Thomas Lutz ⁶, Kirsten Minden ⁷, Tatiana Miraval ⁸, Mahmood M. T. M. Ally ⁹, Nadina Rubio-Pérez ¹⁰, Elisabeth Gervais ¹¹, Riana van Zyl ¹², Robert Wong ¹³, Marleen Nys ¹⁴, Alberto Martini ¹⁵ and Hermine Brunner ¹⁶, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Steve Biko Academic Hospital, University of Pretoria, Pretoria, South Africa, ⁵Pédiatrie 1, CHU Hautepierre, Strasbourg, France, ⁶Heidelberg University Hospital, Heidelberg, Germany, ⁷German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ⁸Clínica San Gabriel, Lima, Peru, ⁹University of Pretoria, Pretoria, South Africa, ¹⁰University Hospital Dr. José Eleuterio González, Monterrey, Mexico, ¹¹CHU de Poitiers, Rheumatology, Poitiers, France, ¹²University of the Free State, Bloemfontein, South Africa, ¹³Bristol-Myers Squibb, Princeton, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: In EU, abatacept (ABA) with MTX is approved in patients (pts) with polyarticular-course JIA (pJIA), as young as 2 years (SC) and 6 years…
Abstract Number: 1816 • 2019 ACR/ARP Annual Meeting
Psoriasis Associated with Anti-Tumor Necrosis Factor-Alpha Therapies in Children with Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis, and Chronic Noninfectious Osteomyelitis
Lisa Buckley¹, Rui Xiao ¹, Marissa Perman ², Andrew Grossman ² and Pamela F. Weiss ², ¹Children's Hospital of Philadelphia, Philadelphia, ²Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: TNF-alpha inhibiting therapies (TNFi) are a cornerstone of treatment for inflammatory conditions such as IBD, JIA, and chronic noninfectious osteomyelitis (CNO) but have been increasingly…
Abstract Number: 1817 • 2019 ACR/ARP Annual Meeting
Arthropathy of Down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change
Charlene Foley¹, Derek Deely ², Emma Jane MacDermott ² and Orla Killeen ², ¹Great Ormond Street Hospital, London, Ireland, ²National Centre for Paediatric Rheumatology (NCPR), Our Lady's Children's Hospital Crumlin (OLCHC), Dublin, Ireland
Background/Purpose: Incidence and prevalence of arthropathy of Down syndrome (A-DS) is increased. It is rarely recognised at onset and remains under-diagnosed. Children with A-DS are therefore…
Abstract Number: 1818 • 2019 ACR/ARP Annual Meeting
Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
Laura Coates¹, Sreekumar Pillai ², Lu Zhang ², David Adams ², Lisa Kerr ², Maja Hojnik ², Gaia Gallo ², Ivo Valter ³, Hasan Tahir ⁴, Vinod Chandran ⁵, Philip Mease ⁶ and Arthur Kavanaugh ⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Center for Clinical and Basic Research, Tallinn, Estonia, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that may lead to serious disability if not appropriately treated. Data on the effect of treatment…
Abstract Number: 1819 • 2019 ACR/ARP Annual Meeting
The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index
Sarah Sacks¹, Kathryn Rigler ² and Antoni Chan ², ¹Royal Berkshire Hospital, Maidenhead, United Kingdom, ²Royal Berkshire Hospital, Reading, United Kingdom
Background/Purpose: Currently the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Spinal pain are used to assess whether a patient with Axial Spondyloarthritis (AxSpA) requires…
Abstract Number: 1820 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient
Uta Kiltz¹, Eerik Ahomaa ², Björn Bühring ³, Xenofon Baraliakos ⁴ and Jürgen Braun ⁵, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, ³Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Physical function in axial spondyloarthritis (axSpA) usually assessed by the BASFI questionnaire is an established core domain of that disease. There is evidence that…
Abstract Number: 1821 • 2019 ACR/ARP Annual Meeting
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Ana-Maria Orbai ¹, Rocco Ballerini ², Richard C. Chou ³, Stephen Rozzo ², Alan Mendelsohn² and Luis R. Espinoza ⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ³University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY, USA, Buffalo, NY, ⁴Section of Rheumatology, LSU Health Sciences Center, New Orleans, LA, New Orleans, LA
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate-to-severe plaque psoriasis. A randomized, double-blind, multidose, placebo (PBO)-controlled, phase 2b study (NCT02980692)…
Abstract Number: 1822 • 2019 ACR/ARP Annual Meeting
6 and 12-month Drug Retention Rates and Treatment Outcomes in 941 Patients with Axial Spondyloarthritis Treated with Secukinumab in Routine Clinical Practice in 12 European Countries in the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Johan Askling ², Catalin Codreanu ³, Herman Mann ⁴, Anne Gitte Loft ⁵, Manuel Pombo-Suarez ⁶, Ziga Rotar ⁷, Tore Kvien ⁸, Maria José Santos ⁹, Anna Mari Hokkanen ¹⁰, Florenzo Iannone ¹¹, Bjorn Gudbjornsson ¹², Fatos Onen ¹³, Lennart Jacobsson ¹⁴, Ruxandra IONESCU ¹⁵, Karel Pavelka ⁴, Carlos Sánchez-Piedra ¹⁶, Matija Tomsic ¹⁷, Joe Sexton ¹⁸, Helena Santos ¹⁹, Jenny Österlund ²⁰, Alberto Cauli ²¹, Arni Jon Geirsson ²², Servet Akar ²³, Adrian Ciurea ²⁴, Gareth Jones ²⁵, Irene van der Horst-Bruinsma ²⁶, Cecilie Heegaard Brahe ²⁷, Stylianos Georgiadis ²⁸, Lykke Midtbøll Ørnbjerg ²⁷, Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Karolinska Institutet, Stockholm, Sweden, ³Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁶Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ⁷UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ⁸Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ¹⁵SPITALUL CLINIC SFANTA MARIA, Bucharest, ¹⁶Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁷Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ¹⁸Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁹Instituto Português de Reumatologia (IPR), Lisbon, Portugal, ²⁰ROB-FIN registry, Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²¹Universitá di Cagliari, Cagliari, Italy, ²²Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ²⁴University Hospital Zürich, Zürich, Switzerland, ²⁵University of Aberdeen, Aberdeen, United Kingdom, ²⁶Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁷Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁸DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Secukinumab is a fully human IgG1 monoclonal antibody targeting interleukin-17A. There is a lack of real-life evidence on secukinumab retention rates and treatment outcomes…
Abstract Number: 1823 • 2019 ACR/ARP Annual Meeting
Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity
Fardina Malik¹, Irvine Levine ², Gabrielle Castillo ¹, Brian Jaros ², Erin Alaia ¹, Justin Ream ², Jordan E. Axelrad ¹, David P. Hudesman ¹ and Jose Scher ³, ¹New York University School of Medicine, New York, NY, ²New York University School of Medicine, New York, ³Division of Rheumatology, New York University School of Medicine and NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: Prevalence of sacroiliitis (SI) in Crohn’s disease (CD) varies widely (range 4% -39%), depending on criteria utilized to define the disease (e.g. inflammatory back…
Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Sarah Patterson¹, Laura Trupin ¹, Cristina Lanata ¹, Louise Murphy ², Wendy Hartogenesis ¹, Maria Dall'Era ¹, Jinoos Yazdany ³ and Patricia Katz ¹, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…
Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Michelle Petri¹, Jessica Li ¹, John Conklin ², Tyler O'Malley ³, Jo-Anne Ligayon ², Leilani Wolover ² and Thierry Dervieux ², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen, Vista, CA, ³Exagen, Oceanside, CA
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…
Abstract Number: 1826 • 2019 ACR/ARP Annual Meeting
Describing Intra-Individual Cognitive Function Course over Time in Lupus Patients: Persistent and Fluctuating Cognitive Impairment, Affected Cognitive Domains, and Severity
Oshrat Tayer-Shifman¹, Dorcas Beaton ², Robin Green ³, Lesley Ruttan ³, Joan Wither ⁴, Maria Tartaglia ⁵, Mahta Kakvan ¹, Sabrina Lombardi ³, Nicole Anderson ¹, Jiandong Su ¹, Dennisse Bonilla ¹, Moe Zandy ¹, May Choi ⁶, Marvin Fritzler ⁶ and Zahi Touma ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²St. Michael's Hospital, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE). The course of CI in SLE patients has been described as persistent…
Abstract Number: 1827 • 2019 ACR/ARP Annual Meeting
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Stanley Moore ¹, Hsin-Hsuan Juo ¹, Christoffer Nielsen ², Helena Tyden ³, Anders Bengtsson ³ and Christian Lood¹, ¹University of Washington, Seattle, ²Statens Serum Institut, Copenhagen, Denmark, ³Lund University, Lund, Sweden
Background/Purpose: Neutrophil activation, including formation of neutrophil extracellular traps (NETs), is essential in host defense. However, NET formation has also been linked to inflammation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].